Our Story
Targeted biologic therapy to increase the efflux of LDL cholesterol from plaques directly by increasing Apo-A1, high-quality functional HDL, reduce plaque burden and address the associated CAD and PAD
Regio Biosciences Today
PIONEERING
The development of novel therapies to reduce plaque in the peripheral arteries and heart for the treatment of atherosclerosis
SPIN-OUT FROM BIG PHARMA
Lead asset, REG-101, is a Phase 2 antibody exclusively licensed from big pharma with established human proof of mechanism and de-risked clinical profile
LEADERSHIP TEAM
Has significant cardiovascular disease drug and biologics development experience and direct involvement with the program while working in big pharma
Our Team
Experienced Team with Disease Expertise.
Leadership Team
Executive Team and Founder’s Approved Drugs: Onglyza, Kombiglyze, Qtern, Imfinzi, Moxetumomab, Fasenra, Sliq, Maxalt, Singulair, Crixivan, Vioxx, Emend, Daytrana and Multiple influenza vaccines and diagnostics.
Team members directed the development of REG-101 as well as multiple similar programs in the fields of cardiovascular, metabolism and renal disease.
Senior Advisory Board
Advisory Board members formerly associated with AZ/MedImmune and have prior experience with REG-101.
Technical & Business Advisors
Connie Hess, MD
Clinician-scientist at CPC, interventional cardiologist, MD from Harvard, trained at Massachusetts General Hospital, cardiology fellowship and Masters degree in Health Science at Duke